An experimental drug could help to improve movement for patients with spinal cord injuries. NVG-291, an injectable peptide, has been tested in a phase 2 trial with eligible patients — some of whom ...
An experimental drug could help young people with a rare form of ALS, researchers at New York’s Columbia University Irving Medical Center announced on Thursday. Known as “ulefnersen,” the therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results